Information Provided By: 
Fly News Breaks for July 17, 2017
ICPT, CBAY
Jul 17, 2017 | 09:36 EDT
H.C. Wainwright analyst Ed Arce raised his price target for CymaBay (CBAY) to $12 saying the Phase 2 results of seladelpar in primary biliary cholangitis "are more robust" than Intercept Pharmaceutical's (ICPT) Ocaliva. The analyst notes that his new target reflects increased confidence in the approvability and market potential of seladelpar. He has a Buy rating on CymaBay.
News For CBAY;ICPT From the Last 2 Days
CBAY
Apr 23, 2024 | 08:31 EDT
New option listings for April 23rd include Express Inc (EXPRQ). Option delistings effective April 23rd include PGT Innovations Inc (PGTI), NGM Biopharmaceuticals Inc (NGM), Karuna Therapeutics Inc (KRTX), KINNATE BIOPHARMA INC (KNTE), Daseke Inc (DSKE), Tritium Dcfc Ltd (DCFC), Xtrackers MSCI All China Equity ETF (CN), CymaBay Therapeutics Inc (CBAY), Alteryx Inc (AYX), XTRACKERS MSCI CHINA A INCLUSION EQUITY ETF (ASHX), Recro Pharma, Inc. (SCTL), Splunk Inc (SPLK), and Textainer Group Holdings Limited (TGH).
